Last reviewed · How we verify
Methylpartricin (MEPARTRICIN)
Methylpartricin (generic name: MEPARTRICIN) is a mepartricin drug. It is currently in Phase 2 development.
Mepartricin is thought to work by inhibiting a specific enzyme or pathway, but the exact mechanism is not well understood.
Mepartricin is a small molecule drug in the mepartricin class, but specific details about its development, commercial status, and approved indications are not available. As a result, there is limited information about its target, pharmacokinetics, and safety profile. Further research is needed to understand the clinical utility and potential risks associated with mepartricin. The current lack of information on its development and approval status suggests that it may not be a commercially available or widely used medication. More information is required to provide a comprehensive summary of mepartricin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEPARTRICIN |
|---|---|
| Drug class | mepartricin |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a factory, and enzymes are the workers that help make important products. Mepartricin is like a tool that tries to stop one of these workers from doing their job, but we're not entirely sure which worker it targets or how it affects the factory's overall production.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylpartricin CI brief — competitive landscape report
- Methylpartricin updates RSS · CI watch RSS
Frequently asked questions about Methylpartricin
What is Methylpartricin?
How does Methylpartricin work?
What is the generic name of Methylpartricin?
What drug class is Methylpartricin in?
What development phase is Methylpartricin in?
Related
- Drug class: All mepartricin drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing